Mr. Dustin Tel Hager, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 800 S Main Ave, Rugby, ND 58368 Phone: 701-776-5261 |
Nicole Micah Lemieux, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 800 S Main Ave, Rugby, ND 58368 Phone: 701-776-5235 |
Gail L Danielson, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 800 S Main Ave, Rugby, ND 58368 Phone: 701-776-5235 Fax: 701-776-5297 |
Marilyn A Kitzman, FNP, PA-C Physician Assistant Medicare: Not Enrolled in Medicare Practice Location: 800 3rd Ave Sw, Rugby, ND 58368 Phone: 701-776-5235 Fax: 701-776-5297 |
Heidi Schmaltz, PA-C Physician Assistant Medicare: Accepting Medicare Assignments Practice Location: 800 S Main Ave, Rugby, ND 58368 Phone: 701-776-5261 |
News Archive
European scientists have developed the most accurate method yet for predicting the doses of radiation that astronauts will receive aboard the orbiting European laboratory module, Columbus, attached to the ISS this week.
The U.S. Food and Drug Administration today announced, in accordance with longstanding U.S. obligations under the Montreal Protocol on Substances that Deplete the Ozone Layer, seven metered-dose inhalers (MDI) used to treat asthma and chronic obstructive pulmonary disease (COPD) will be gradually removed from the U.S. marketplace. These inhalers contain ozone-depleting chlorofluorocarbons (CFCs), which are propellants that move medication out of the inhaler and into the lungs of patients.
HealthGrades, the nation's leading independent ratings organization, today made available to organ transplant patients a list of those hospitals with the best track record for survival and chances of receiving a donor organ. HealthGrades annual evaluation of the nation's top-performing hospitals in organ transplantation includes clinical quality data, based on patient outcomes, for each of the 210 adult acute care hospitals that perform transplants.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the attention-deficit/hyperactivity disorder (ADHD) drug market in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan will fluctuate modestly over the next decade, decreasing from $5 billion in 2009 to a trough in 2013 before climbing to $4.1 billion in 2019.
› Verified 5 days ago